Center for Cancer Research
National Cancer Institute
United States of America
Dr. Alessio Giubellino received his M.D. from the University of Torino Medical School in 1999 and trained in the Division of Molecular Oncology of the same University studying cell signal transduction with emphasis on HGF/c-Met signaling. He joined the NCI's Urologic Oncology Branch in 2004 under the mentorship of Dr. Donald Bottaro. Dr. Giubellino research has focused on cancer biomarkers and on pre-clinical drug development, specifically targeting aberrant protein signaling networks associated with cancer as a new therapeutic strategy.
Liu F, Worthy KM, Bindu L, Giubellino A, Bottaro DP, Fisher RJ, Burke Jr TR. Utilization of achiral alkenyl amines for the preparation of high affinity Grb2 SH2 domain-binding macrocycles by ring-closing metathesis. Organic & biomolecular chemistry. 2007;5(2):367-72.
Giubellino A, Gao Y, Lee S, Lee MJ, Vasselli JR, Medepalli S, Trepel JB, Burke TR, Bottaro DP. Inhibition of tumor metastasis by a growth factor receptor bound protein 2 src homology 2 domain–binding antagonist. Cancer research. 2007 Jul 1;67(13):6012-6.
Giubellino A, Burke TR, Bottaro DP. Grb2 signaling in cell motility and cancer. Expert opinion on therapeutic targets. 2008 Aug 1;12(8):1021-33.